The deal size was raised to $750M in common stock from $650M in common stock and the range was $95.00-$97.98. Goldman Sachs and Leerink acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed announces $650M common stock offering
- Insmed price target raised to $106 from $99 at RBC Capital
- Insmed price target raised to $102 from $90 at Morgan Stanley
- Mizuho ups Insmed target on ‘grand slam’ PAH data
- Buy Rating on Insmed Driven by Promising Phase 2 Results and Strategic Phase 3 Approach for PAH Treatment